Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia

Graefes Arch Clin Exp Ophthalmol. 2012 Nov;250(11):1697-9. doi: 10.1007/s00417-011-1798-2. Epub 2011 Aug 24.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Capillary Permeability
  • Female
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Retina / pathology
  • Retinal Telangiectasis / drug therapy*
  • Retinal Telangiectasis / physiopathology
  • Retreatment
  • Retrospective Studies
  • Subretinal Fluid
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab